News

Safety Shot Continues Scientific Development with Double-Blind Placebo-Controlled Trial Designed to Assess the Effects of Safety Shot on Blood and Breath Alcohol Levels

Topline data expected Q1 2024Safety Shot is designed to make you feel good faster by reducing blood alcohol levels and…

2 years ago

NurExone Reports Third Quarter 2023 Financial Results and Provides Corporate Update

TORONTO and HAIFA, Israel, Nov. 24, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company”…

2 years ago

Compass Pathways to participate in upcoming Evercore investor conference

LONDON, Nov. 24, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access…

2 years ago

NexgenRx Inc. Announces Q3 2023 Quarterly Results with Continued Revenue Growth and Positive EBITDA

TORONTO, ON / ACCESSWIRE / November 23, 2023 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its…

2 years ago

Medicure Announces FDA Provides Complete Approval to Enroll Patients in Its Pivotal Phase 3 Trial for Treatment of Rare Pediatric Disease

WINNIPEG, MB / ACCESSWIRE / November 23, 2023 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused…

2 years ago

iZafe Group and Atea Sweden Have Entered into an Agreement with VGR in the Field of Welfare Technology

STOCKHOLM, SE / ACCESSWIRE / November 23, 2023 / iZafe Group (STO:IZAFE-B) iZafe Group AB ("iZafe Group") announces that the…

2 years ago

Justera Secures Supply Agreement for Emart24 to Expand Global Reach

Toronto, Ontario--(Newsfile Corp. - November 23, 2023) - Justera Health Ltd. (CSE: VTAL) (OTC Pink: SCRSF) ("Justera" or the "Company")…

2 years ago

Curium Completes Patient Enrollment of Phase 3 ECLIPSE Trial Ahead of Schedule

ST. LOUIS, Nov. 23, 2023 (GLOBE NEWSWIRE) -- Curium, a global leader in nuclear medicine, announced today the successful completion…

2 years ago

MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen Sclerosus

MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen Sclerosus MC2-25 VLS…

2 years ago

MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen Sclerosus

MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen Sclerosus MC2-25 VLS…

2 years ago